BRPI0519788A2 - antagonistas do receptor 5-ht7 - Google Patents

antagonistas do receptor 5-ht7

Info

Publication number
BRPI0519788A2
BRPI0519788A2 BRPI0519788-0A BRPI0519788A BRPI0519788A2 BR PI0519788 A2 BRPI0519788 A2 BR PI0519788A2 BR PI0519788 A BRPI0519788 A BR PI0519788A BR PI0519788 A2 BRPI0519788 A2 BR PI0519788A2
Authority
BR
Brazil
Prior art keywords
compounds
receptor antagonists
receptor
acenaphthylen
aza
Prior art date
Application number
BRPI0519788-0A
Other languages
English (en)
Inventor
Torrens Jover
Yenes Minguez
Mas Prio
Romero Alonso
Dordal Zueras
Buschmann Alberto
Helmut Henrich
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of BRPI0519788A2 publication Critical patent/BRPI0519788A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

ANTAGONISTAS DO RECEPTOR 5-HT7. A invenção refere-se a compostos que têm atividade farmacológica face ao receptor 5-HT7, e mais particularmente, a alguns compostos de sulfonamida substituidos com 212a,4,5-tetrahidro-1H-3-aza-acenaftileno, a processos de preparação de tais compostos, a composições farmacêuticas que os compreendem e ao seu uso para o tratamento e/ou a profilaxia de uma doença na qual o 5-HT está envolvido, tal como distúrbios do SNC.
BRPI0519788-0A 2004-12-28 2005-12-27 antagonistas do receptor 5-ht7 BRPI0519788A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04380280A EP1676840A1 (en) 2004-12-28 2004-12-28 5-HT7 Receptor antagonists
US11/048,991 US20060142321A1 (en) 2004-12-28 2005-02-02 5-HT7 receptor antagonists
PCT/EP2005/014044 WO2006069775A1 (en) 2004-12-28 2005-12-27 5-ht7 receptor antagonists

Publications (1)

Publication Number Publication Date
BRPI0519788A2 true BRPI0519788A2 (pt) 2009-03-17

Family

ID=34931895

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519788-0A BRPI0519788A2 (pt) 2004-12-28 2005-12-27 antagonistas do receptor 5-ht7

Country Status (13)

Country Link
US (2) US20060142321A1 (pt)
EP (2) EP1676840A1 (pt)
JP (1) JP2008525512A (pt)
KR (1) KR20070098882A (pt)
CN (1) CN101389608A (pt)
AT (1) ATE518836T1 (pt)
AU (1) AU2005321462A1 (pt)
BR (1) BRPI0519788A2 (pt)
CA (1) CA2591201A1 (pt)
ES (1) ES2370877T3 (pt)
MX (1) MX2007007893A (pt)
RU (1) RU2007128964A (pt)
WO (1) WO2006069775A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1875899A1 (en) * 2006-06-29 2008-01-09 Laboratorios Del Dr. Esteve, S.A. Use of 5HT7 receptor agonists for the treatment of pain
WO2012058769A1 (en) * 2010-11-03 2012-05-10 Mcmaster University Method of treating mucosal inflammation
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ193654A (en) 1979-05-16 1984-08-24 Wuelfing Johann A Naphthalene sulphonamido-alkyl-piperidines,pyrrolidines or piperazines and pharmaceutical compositions
DE3276313D1 (en) 1981-09-24 1987-06-19 Beecham Wuelfing Gmbh & Co Kg Sulphonamides
EP0883613A1 (en) 1996-02-09 1998-12-16 Smithkline Beecham Plc Sulfonamide derivatives as 5ht7 receptor antagonists
GB9612884D0 (en) 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds
JP2000512646A (ja) * 1996-06-25 2000-09-26 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ７受容体アンタゴニストとしてのスルホンアミド誘導体
EP0937715B1 (en) 1996-06-28 2005-06-01 Meiji Seika Kaisha Ltd. Tetrahydrobenzindole compounds
AU1558899A (en) 1997-11-10 1999-05-31 F. Hoffmann-La Roche Ag Isoquinoline derivatives for use against cns disorders
AU4698299A (en) * 1998-06-30 2000-01-17 Du Pont Pharmaceuticals Company 5-HT7 receptor antagonists
GB0128885D0 (en) 2001-12-03 2002-01-23 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
KR20070098882A (ko) 2007-10-05
US20060142321A1 (en) 2006-06-29
US20090264458A1 (en) 2009-10-22
JP2008525512A (ja) 2008-07-17
ES2370877T3 (es) 2011-12-23
CA2591201A1 (en) 2006-07-06
MX2007007893A (es) 2007-10-03
RU2007128964A (ru) 2009-02-10
CN101389608A (zh) 2009-03-18
ATE518836T1 (de) 2011-08-15
WO2006069775A1 (en) 2006-07-06
EP1676840A1 (en) 2006-07-05
EP1836172A1 (en) 2007-09-26
AU2005321462A1 (en) 2006-07-06
EP1836172B1 (en) 2011-08-03
US7662862B2 (en) 2010-02-16

Similar Documents

Publication Publication Date Title
WO2003028641A3 (en) Mch receptor antagonists
ATE411323T1 (de) Cgrp-rezeptorantagonisten
DE602005020655D1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
ATE493412T1 (de) Spirohydantoin-aryl-cgrp-rezeptorantagonisten
ATE537170T1 (de) Cgrp-rezeptorantagonisten
BRPI0519792A2 (pt) antagonistas do receptor 5-ht7
WO2007019234A3 (en) Aminoethane sulfonamide orexin receptor antagonists
EA200700035A1 (ru) Сульфаматные и сульфамидные производные для лечения эпилепсии и родственных di sorders
ATE466860T1 (de) Cgrp-rezeptorantagonisten
WO2006047196A3 (en) Cgrp receptor antagonists
WO2006038006A3 (en) 5-sulfonyl-1-piperidinyl substituted indole derivatives as 5-ht6 receptor antagonists for the treatment of cns disorders
MX2007001992A (es) Antagonistas del receptor 5-ht7.
DE60229530D1 (de) Substituierte piperazine als modulatoren des melanocortinrezeptors
ATE485269T1 (de) C-verknüpfte zyklische antagonisten des p2y1- rezeptors mit eignung bei der behandlung thrombotischer leiden
NO20092470L (no) Substituerte diazepanforbindelser som orexinreseptorantagonister
ATE293448T1 (de) Benzo(d)azepin-derivative als 5-ht6-rezeptor- antagonisten
JO2355B1 (en) Hereditary calcitonin polypeptide receptor antagonists
CY1110882T1 (el) Ανταγωνιστες υποδοχεων ορεξινης υποκατεστημενης διαζεπανης
DE602004013563D1 (de) Rantagonisten
MX2007002393A (es) Compuestos indolicos sustituidos y su uso como moduladores del receptor de 5-hidroxitriptamina 6 (5-ht6).
DE602005027870D1 (de) Cgrp-rezeptorantagonisten
MX2007001990A (es) Antagonistas del receptor 5-ht7.
BRPI0519788A2 (pt) antagonistas do receptor 5-ht7
ATE513810T1 (de) Aminoalkoxy-aryl-sulfonamidverbindungen und ihre verwendung als 5-ht6-liganden
DE602007004327D1 (de) Einen azepin-kern enthaltende antagonisten des histaminrezeptors

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.